New acid blocker may outperform standard drug for Post-POEM reflux healing

NCT ID NCT06955520

Recruiting now Disease control Sponsor: Asian Institute of Gastroenterology, India Source: ClinicalTrials.gov ↗

First seen Apr 30, 2026 · Last updated May 18, 2026 · Updated 5 times

Summary

This study tests whether Vonaprazan, a newer acid blocker, works better than the standard drug Esomeprazole for healing moderate-to-severe esophagitis caused by acid reflux after POEM surgery for achalasia. About 300 adults who had POEM and developed reflux esophagitis will take one of the two drugs for 8 weeks. The main goal is to see which drug heals the esophagus better, as seen on endoscopy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asian Institute of Gastroenterology /Aig Hospitals
RECRUITING

Hyderabad, Telangana, 500082, India

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GERD